Literature DB >> 25394725

The improved accuracy of planar bone scintigraphy by adding single photon emission computed tomography (SPECT-CT) to detect skeletal metastases from prostate cancer.

L C McLoughlin1, F O'Kelly2, C O'Brien3, M Sheikh2, J Feeney3, W Torreggiani3, J A Thornhill4.   

Abstract

BACKGROUND: Planar bone scintigraphy (PBS) is a standard radiological technique to detect skeletal metastases from prostate cancer (PC), the addition of SPECT-CT to PBS improves its diagnostic accuracy. The aim of this study was to assess the additional value of targeted SPECT-CT with PBS in detecting skeletal metastasis form prostate cancer, considering resource implications in an Irish hospital setting.
METHODS: 54 PC patients with increased radiotracer uptake on PBS were retrospectively recruited from 2012 to 2013. All underwent targeted evaluation with SPECT-CT. PBS and SPECT-CT images were reviewed by two nuclear medicine radiologists and reported independently. The final diagnosis was made based on the CT finding corresponding to the area of radiotracer uptake.
RESULTS: The mean age was 70.9 years (48-88 years) and median PSA at presentation was 13.9 ng/ml (4.2-215 ng/ml). 68.5 % (n = 37) men received treatment for PC while 31.5 % (n = 17) patients had not received treatment prior to PBS. 164 areas of increased radiotracer uptake were identified on PBS; 13 areas were characterised as metastatic on SPECT-CT; iliac bone (n = 3), ribs (n = 1), skull (n = 2), sacrum (n = 1), ischium (n = 1), femur (n = 3), thoracic spine (n = 1) and cervical spine (n = 1). 151 areas were characterised as benign on SPECT-CT. One area of increased radiotracer uptake in the ribs was subsequently described as indeterminate after evaluation with SPECT-CT.
CONCLUSION: SPECT-CT improves the diagnostic accuracy of PBS in detecting skeletal metastasis from PC and is superior to PBS alone in differentiating benign from malignant lesions. Notwithstanding resource implications of increased cost, specialist equipment and specialist manpower hours; we recommend the use of SPECT-CT in conjunction with PBS for targeted evaluation of suspicious bony lesions in this cohort of patients.

Entities:  

Keywords:  Bone metastases; Diagnosis; Planar bone scintigraphy; Prostate cancer; SPECT-CT

Mesh:

Substances:

Year:  2014        PMID: 25394725     DOI: 10.1007/s11845-014-1228-7

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  16 in total

1.  Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer.

Authors:  H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel
Journal:  J Nucl Med       Date:  2001-12       Impact factor: 10.057

Review 2.  Radionuclide bone imaging: an illustrative review.

Authors:  Charito Love; Anabella S Din; Maria B Tomas; Tomy P Kalapparambath; Christopher J Palestro
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

3.  Characterization of focal bone lesions in the axial skeleton: performance of planar bone scintigraphy compared with SPECT and SPECT fused with CT.

Authors:  Klaus Strobel; Cyrill Burger; Burkhardt Seifert; Daniela B Husarik; Jan D Soyka; Thomas F Hany
Journal:  AJR Am J Roentgenol       Date:  2007-05       Impact factor: 3.959

4.  The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate.

Authors:  Vincent Helyar; Hosahalli K Mohan; Tara Barwick; Lefteris Livieratos; Gopinath Gnanasegaran; Susan E M Clarke; Ignac Fogelman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-17       Impact factor: 9.236

5.  Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT.

Authors:  Daisuke Utsunomiya; Shinya Shiraishi; Masanori Imuta; Seiji Tomiguchi; Koichi Kawanaka; Shoji Morishita; Kazuo Awai; Yasuyuki Yamashita
Journal:  Radiology       Date:  2005-11-22       Impact factor: 11.105

6.  Beware of the focal uptake at the ischium on the bone scan in prostate cancer.

Authors:  Fahim U Hassan; Hosahalli Krishnamurthy Mohan; Gopinath Gnanasegaran; Sanjay Vijayanathan; Ignac Fogelman
Journal:  Nucl Med Commun       Date:  2011-04       Impact factor: 1.690

Review 7.  Radiological imaging for the diagnosis of bone metastases.

Authors:  L D Rybak; D I Rosenthal
Journal:  Q J Nucl Med       Date:  2001-03

8.  The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.

Authors:  Einat Even-Sapir; Ur Metser; Eyal Mishani; Gennady Lievshitz; Hedva Lerman; Ilan Leibovitch
Journal:  J Nucl Med       Date:  2006-02       Impact factor: 10.057

9.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET.

Authors:  H Schirrmeister; A Guhlmann; K Elsner; J Kotzerke; G Glatting; M Rentschler; B Neumaier; H Träger; K Nüssle; S N Reske
Journal:  J Nucl Med       Date:  1999-10       Impact factor: 10.057

10.  Whole-body SPECT/CT for bone scintigraphy: diagnostic value and effect on patient management in oncological patients.

Authors:  H Palmedo; C Marx; A Ebert; B Kreft; Y Ko; A Türler; R Vorreuther; U Göhring; H H Schild; T Gerhardt; U Pöge; S Ezziddin; H-J Biersack; H Ahmadzadehfar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-08-24       Impact factor: 9.236

View more
  8 in total

1.  Is there still a role for computed tomography and bone scintigraphy in prostate cancer staging? An analysis from the EUREKA-1 database.

Authors:  D Gabriele; D Collura; M Oderda; I Stura; C Fiorito; F Porpiglia; C Terrone; M Zacchero; C Guiot; P Gabriele
Journal:  World J Urol       Date:  2015-08-15       Impact factor: 4.226

2.  Three-minute SPECT/CT is sufficient for the assessment of bone metastasis as add-on to planar bone scintigraphy: prospective head-to-head comparison to 11-min SPECT/CT.

Authors:  Helle D Zacho; José A Biurrun Manresa; Ramune Aleksyniene; June A Ejlersen; Joan Fledelius; Henrik Bertelsen; Lars J Petersen
Journal:  EJNMMI Res       Date:  2017-01-05       Impact factor: 3.138

3.  Predicting castration-resistant prostate cancer after combined androgen blockade.

Authors:  Miao He; Haina Liu; Jingyi Cao; Qian Wang; Haiting Xu; Yufeng Wang
Journal:  Oncotarget       Date:  2017-11-01

4.  Skeletal standardized uptake values obtained by quantitative SPECT/CT as an osteoblastic biomarker for the discrimination of active bone metastasis in prostate cancer.

Authors:  Ichiei Kuji; Tomohiko Yamane; Akira Seto; Yota Yasumizu; Suguru Shirotake; Masafumi Oyama
Journal:  Eur J Hybrid Imaging       Date:  2017-10-12

5.  Clinical study of 99mTc-3P-RGD2 peptide imaging in osteolytic bone metastasis.

Authors:  Guoqiang Shao; Wei Gu; Muhong Guo; Shiming Zang; Jinjing Fu; Shuang Liu; Feng Wang; Zizheng Wang
Journal:  Oncotarget       Date:  2017-04-27

6.  Differentiation of Cervical Spine Osteoradionecrosis and Bone Metastasis After Radiotherapy Detected by Bone Scan in Patients With Nasopharyngeal Carcinoma: Role of Magnetic Resonance Imaging.

Authors:  Xi Zhong; Li Li; Bingui Lu; Hainan Zhang; Lu Huang; Xinjia Lin; Jiansheng Li; Jian Zhang
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

Review 7.  The surgical management and treatment of metastatic lesions in the proximal femur: A mini review.

Authors:  Helin Feng; Jin Wang; Jianfa Xu; Wei Chen; Yingze Zhang
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

8.  Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression.

Authors:  Bo Yan; Yan Li; Shaoju Min; Peng Zhang; Bin Xu; Zhen Wang; Wei Zhang; Jiasheng Chen; Guangheng Luo; Chunxiao Liu
Journal:  Biomed Res Int       Date:  2020-04-06       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.